FDA panel: Benefit of Baxter's immune therapy outweighs risk

July 31 (Reuters) - The benefits associated with Baxter International Inc's experimental treatment for certain diseases of the immune system outweigh the risks, an advisory committee to the U.S. Food and Drug Administration concluded on Thursday, paving the way for approval of the therapy.